Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,283.9
3.9 (0.12%)

 

  • STI Straits Times Index
    3,283.9
    3.9 (0.12%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,530.3
    -12.6 (-0.82%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,127.8
    15.1 (0.06%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,558.2
    -11.7 (-0.33%)
    Index delayed 15 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,043.2M
  • Value: 1,204.6M
  • Rise: 113
  • Fall: 196
  • Unch: 451

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Shen Yao0.003-
DISA0.008-0.001
Sembcorp Marine0.083+0.001
Jiutian Chemical0.083+0.001
RH PetroGas0.189-0.002
Beverly JCG0.002-
ThaiBev0.640-
HGH0.012+0.001
Oceanus0.029-
Genting Sing0.780-

World Indices

World Indices
Name Last Change
Nasdaq 14,506.9 -386.9
HSI 24,127.8 +15.1
HSCEI 8,441.7 -7.3
Jakarta 6,592.0 -22.1
Nikkei 225 27,467.2 -790.0
SSE Comp 3,558.2 -11.7
Shanghai A 3,728.8 -12.3
Shanghai B 287.0
KOSPI 2,842.3 -22.0

Nikkei 225 updated at end-of-day. Other Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS
Updated on 18 Jan 2022 (End of trading day)
Last (USD): 30.540 Change: -0.530 High: 31.220 Remarks: -
Change (%): -1.71 Low: 29.870
Open 31.165 Yesterday's Close 31.07
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 248,284 Cumulative Value

Company Background

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment covers all activities related to oncology/immunology including sales, marketing, manufacturing and research and development with respect to drugs and drug candidates. The Other Ventures segment includes all other HUTCHMED businesses. The company was founded in June 2000 and is headquartered in Hong Kong.

Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.72716 Trailing EPS (USD) b -0.72716 NAV (USD) c 5.6956
PE a - Trailing PE d - Price / NAV c 5.3620
Dividend Yield (%) e - Cash In Hand (USD) f 3.3975 Issued & Paid-up Shares g 172,906,000
Piotroski F Score 3 Market Cap (M) 5,280.549 Free Float (%) 97.7
Return on Equity (ROE) (%) h n.m. Revenue Growth (%) TTM i 11.268
Net Earnings Growth (%) j -18.586 Net Debt/Equity k Net Cash
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 31 Dec 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --3.410
-10.04 %
10 Days --1.050
-3.32 %
20 Days --4.530
-12.92 %
Medium Term Return 3 Months --1.690
-5.24 %
6 Months --10.890
-26.29 %
1 Year --2.650
-7.98 %
Long Term Return 2 Years -+4.850
+18.88 %
3 Years -+8.290
+37.26 %
5 Years -+16.570
+118.61 %
Annualised Return Annualised --
+16.93 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS NASDAQ 5,280.549 - - 5.3620 -
Industry Pharmaceuticals: Major NASDAQ 2,048.560 81.192 91.614 2.6735 0.028
Local Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 185,432.192 58.020 126.059 4.6657 -
Local Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 131,839.850 9.392 19.038 1.7580 -
Local Peer ROYALTY PHARMA PLC NASDAQ 24,481.256 25.108 31.273 4.2260 0.476
Local Peer VIATRIS INC NASDAQ 18,213.413 - - 0.8615 -
Local Peer REPLIGEN CORP NASDAQ 10,317.387 172.169 86.789 6.0150 -
Local Peer EVOTEC SE SPON ADS EACH REP 0.50 ORD SHS NASDAQ 6,935.790 972.933 23.544 6.0287 -
Local Peer ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS NASDAQ 6,627.682 - - 5.7558 -
Local Peer LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS NASDAQ 6,281.354 - - 27.8097 -
Local Peer CUREVAC NV NASDAQ 4,198.048 - - - -
Local Peer CEREVEL THERAPEUTICS HLDGS INC NASDAQ 3,795.744 - - 6.0338 -
Local Peer APELLIS PHARMACEUTICALS INC NASDAQ 3,689.104 - - -64.3491 -
Local Peer KARUNA THERAPEUTICS INC NASDAQ 3,328.211 - - 6.4211 -
Other Local Peers GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), EQRX INC (NASDAQ), OPKO HEALTH INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), IMMUNITYBIO INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), ERASCA INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), AMYLYX PHARMACEUTICALS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), PROCAPS GROUP S.A. (NASDAQ), GH RESEARCH PLC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), GOSSAMER BIO INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), ICOSAVAX INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), PETIQ INC (NASDAQ), KRONOS BIO INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), PHARVARIS NV (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), CINCOR PHARMA INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), 2SEVENTY BIO INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), VERU INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), TRICIDA INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), ALLAKOS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), GENERATION BIO CO (NASDAQ), XILIO THERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), AC IMMUNE SA (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), ANNEXON INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), EVOLUS INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), IMMUNIC INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), COMPASS THERAPEUTICS INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), XOMA CORP</